AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03609866 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: inferior limb passive mobilization
Description: it will be performed a passive mobilization technique on the patient
Study NCT06216756 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: osteochondral transplant on the femoral condyle
Description: Patients who have a symptomatic full-thickness cartilage lesion (Grade 3 or 4) on the femoral condyle, in a mechanically stable knee, or is being mechanically stabilized in the same procedure, between 2.0-8.0 cm2 in size, and cystic changes requiring osseous repair present in less than or equal to 12 mm of subchondral bone will undergo a osteochondral transplant by removing the damaged cartilage and replacing that cartilage with a cryopreserved osteochondral allograft core.
Study NCT05067270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Citrate
Description: Administered SC infusion.
Study NCT04915495 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: LuViva Advanced Cervical Scan
Description: Multimodal hyperspectral device
Study NCT04786353 — intervention group
Intervention type: OTHER
Intervention: LongCOVIDkidsDK
Description: Exposure: To be identified as an exposure for the current study, children from 0-18 years with at least one positive SARS-CoV-2 test will be identified from COVID-19 data from January 2020 until the last updated version. To be able to identify the parents who will receive the questionnaires we will also need CPR-data on the children's parents.
Study NCT05412706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Patients will receive Niraparib 200-300 mg orally as an individualized weight and platelet-based, flat-fixed, continuous daily dose.~Niraparib will be administered orally once daily in 28-day cycles.
Study NCT06231043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac/Tramadol
Description: Arm Drug1 :Diclofenac 75 mg (3 ml) IM injection by doctor, then followed by normal saline 20 ml IV injection (equal to Tramadol diluted) by nurse.~Arm Drug2 :Normal saline 3 ml IM injection by doctor (equal to Diclofenac 75 mg), then followed by Tramadol 50 mg (1 ml) dilute with normal saline 19 ml (total 20 ml )IV injection by nurse.
Study NCT06231043 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac/Tramadol
Description: Arm Drug1 :Diclofenac 75 mg (3 ml) IM injection by doctor, then followed by normal saline 20 ml IV injection (equal to Tramadol diluted) by nurse.~Arm Drug2 :Normal saline 3 ml IM injection by doctor (equal to Diclofenac 75 mg), then followed by Tramadol 50 mg (1 ml) dilute with normal saline 19 ml (total 20 ml )IV injection by nurse.
Study NCT06401980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: Darolutamide will be supplied in bottles as 300 mg film-coated tablets for oral intake
Study NCT06401980 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: * Docetaxel~* Cabazitaxel~* LuPSMA~* Radium 223~* Olaparib, in case of BRCA1 or 2 mutated or HRR deficient tumors~The standard of care is chosen by the local investigator and respecting the country specific approvals.
Study NCT05159414 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse Electrical Stimulation
Description: Pulse Electrical Stimulation Patients wear our clinical trial device 30mins once a day for 16weeks.
Study NCT05841940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]HLX208
Description: Carbon-14 labeled HLX208
Study NCT05067270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil
Description: Administered SC infusion.
Study NCT05212051 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS005
Description: 30 subjectes in JS005 150mg chort, JS005 300mg chort, and JS005 450mg chort receive JS005 150mg, JS005 300mg and JS005 450mg subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
Study NCT04977739 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention
Description: No intervention
Study NCT05212051 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 subjects in JS005 150mg chort, JS005 300mg chort, and JS005 450mgchort receive the placebo subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
Study NCT05067270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humalog diluent
Description: Administered SC infusion.
Study NCT05230147 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation
Description: Single stimuli are delivered to define the stimulation threshold. High-frequency stimulation with modulated current via skin patches captures posterior horns of the spinal cord.
Study NCT05230147 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Single stimuli are delivered to define the stimulation threshold. High-frequency stimulation is not delivered.
Study NCT06105138 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 200mg Cannabidiol oral solution
Description: 200mg cannabidiol administered in the laboratory prior to a standard dose of alcohol.~The water-soluble product is standardized to 5.0% cannabidiol, 0.0% THC and composed of reverse-osmosis water, gum arabic, cannabidiol, MCT (Medium Chain Triglyceride) oil and citric acid. The same lot of Caliper water soluble CBD was used for both the 30 mg and 200 mg test variable. All CBD was sourced from the same lot of CDB isolate. The Caliper commercial product conforms to all standards set forth by the CDPHE (Colorado Dept of Public Health and Environment).
Study NCT06105138 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 30mg Cannabidiol oral solution
Description: 30mg cannabidiol administered in the laboratory prior to a standard dose of alcohol.~The water-soluble product is standardized to 5.0% cannabidiol, 0.0% THC and composed of reverse-osmosis water, gum arabic, cannabidiol, MCT (Medium Chain Triglyceride) oil and citric acid. The same lot of Caliper water soluble CBD was used for both the 30 mg and 200 mg test variable. All CBD was sourced from the same lot of CDB isolate. The Caliper commercial product conforms to all standards set forth by the CDPHE (Colorado Dept of Public Health and Environment).
Study NCT06105138 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered in the laboratory prior to a standard dose of alcohol.~The placebo was made up for the study and contained reverse-osmosis water, gum arabic, MCT (Medium Chain Triglyceride) oil, citric acid, plus the addition of a natural food color, used at \<0.1%.
Study NCT06154629 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Botanical ingredient
Description: Consumption for 90 days. Subjects should consume one capsule one hour before going to sleep
Study NCT06154629 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Consumption for 90 days. Subjects should consume one capsule one hour before going to sleep
Study NCT05067270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Chloride
Description: Administered SC infusion.
Study NCT05574140 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: The 4-minute breathing maneuver comprised of 2 minutes of normal breathing and 1-min hyperventilation (rate of 30 breaths per minute) followed by a maximal breath-hold. This technique is used in Oxygenation Sensitive CMR, a type of MRI, and will induce a vasoactive response visible in cardiac and cerebral MRI images
Study NCT06217991 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PTST(parachute-tunnel-style technique)for esophagogastrostomy
Description: Suture the gastric remnant at the mark on the back wall of the esophagus.(Don't tighten the suture); Pull the esophageal stump out of the tunnel meanwhile tighten the suture and the gastric stump to close the back wall of the esophagus and the gastric stump together;Cut the back esophageal wall close to the esophageal stump,cut the front gastric wall along line B. Suture the back esophageal wall and the upper edge of the front gastric wall incision from right to left;Remove residual esophageal nail, and suture the back esophageal wall and the lower edge of the gastric incision from right to left. Suture the anterior wall of the stomach at the lower edge of the tunnel with the serosa layer at the lower edge of the front wall of the esophagus stomach anastomosis;Suture the upper edge of the tunnel with the front wall of the esophagus and the left and right lateral walls at the gastric stump suture of the original posterior wall of the esophagus. (all use 3-0 barbed suture continuously)
Study NCT05018286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apraglutide
Description: Apraglutide is a synthetic peptide analogue of GLP-2 under development for treatment of SBS-IF, which acts as a full agonist at the GLP-2 receptor with in vitro potency and selectivity comparable with native GLP-2
Study NCT06075732 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increasing Willingness and Uptake of Influenza, Pneumonia, Meningitis, HZV, and COVID-19 Vaccination
Description: Provide/enhance knowledge, modify attitudes, motivate and provide skills and resources to reduce Influenza, Pneumonia, Meningitis, HZV, and COVID-19 vaccine hesitancy and increase willingness and uptake in Influenza, Pneumonia, Meningitis, HZV, and COVID-19 vaccination.
Study NCT06573853 — intervention group
Intervention type: PROCEDURE
Intervention: Focal Pulsed Field Ablation (PFA)
Description: Patients in the PFA group underwent ablation procedures utilizing a force-sensing PFA catheter for the treatment of PSVT.
Study NCT06573853 — intervention group
Intervention type: PROCEDURE
Intervention: Focal Radiofrequecy Ablation (RFA)
Description: Patients in the PFA group underwent ablation procedures utilizing force-sensing RFA catheters for the treatment of PSVT.
Study NCT06441630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AD-227A
Description: Per Oral, 1 Tablet, Once a day for 8 weeks
Study NCT06441630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-227A
Description: Per Oral, 1 Tablet, Once a day for 8 weeks
Study NCT06441630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-227B
Description: Per Oral, 1 Tablet, Once a day for 8 weeks
Study NCT06036238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Living Intervention (HLI)
Description: The Healthy Living Intervention (HLI) is a brief alcohol counseling intervention developed using the Information, Motivation, and Behavioral skills (IMB) model, a framework in which information, motivation, and behavioral skills are key determinants of health behavior. Participants initiating PrEP will be randomized to either HLI or standard of care alcohol counseling.
Study NCT06441630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AD-227C
Description: Per Oral, 1 Tablet, Once a day for 8 weeks
Study NCT06441630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of AD-227B
Description: Per Oral, 1 Tablet, Once a day for 8 weeks
Study NCT06441630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of AD-227C
Description: Per Oral, 1 Tablet, Once a day for 8 weeks
Study NCT06441630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of AD-227C
Description: Per Oral, 1 Tablet, Once a day for 8 weeks
Study NCT04820179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib + Atezolizumab
Description: All the subjects will be treated with the combination of cabozantinib and atezolizumab until disease progression, unacceptable toxicity or patient consent withdrawal (whichever occurs first).
Study NCT05794139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMD670
Description: Tablets
Study NCT05794139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets
Study NCT06544239 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality basketball asymmetric training
Description: This study established two experimental groups, namely the experimental group and the control group. The experimental group received virtual reality device assisted training, while the control group received traditional training
Study NCT05937776 — intervention group
Intervention type: OTHER
Intervention: Fludeoxyglucose F-18
Description: Given IV
Study NCT05937776 — intervention group
Intervention type: OTHER
Intervention: Gadoterate Meglumine
Description: Given IV
Study NCT06036238 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Participants who are randomized to the control arm will receive basic alcohol counseling through the Ministry of Health if it is provided as standard of care.
Study NCT05347355 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spencer technique along with conventional treatment
Description: Subjects in this group will receive conventional exercises and 7 stages of Spencer technique: (A) extension, (B) flexion, (C) circumduction with compression, (D) circumduction with traction, (E) abduction, (F) internal rotation, (G) lymphatic pump.~Spencer technique will be used to increase range of motion of the glenohumeral joint. The patient will be positioned lying on the side with the affected shoulder above. The therapist will stabilize the shoulder girdle with the proximal hand and the distal hand will provide force into the restrictive barrier of shoulder in 7 different movements. These will be shoulder extension, circumduction with distraction, abduction, adduction with internal rotation and glenohumeral pump. During all the movements, patient will be asked to use muscle energy against the slight resistance offered by the therapist for 3-5 seconds. The exercise will be repeated 3-5 times with rest intervals over 3 sessions per week on alternate days for 4 weeks.
Study NCT05347355 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gongs Mobilization along with conventional treatment
Description: The Gong's mobilization can be done either in high sitting or in side-lying position with the affected shoulder upward. The subject's shoulder will be abducted at 90° so that the humerus will be maintained at vertical position. The elbow joint will be flexed and maintained at 90°; the therapist will maintain this position by placing his/her hand below the subject's elbow. The humeral head will be pressed from anterior to posterior direction with the other hand. The therapist will hold the vertical axis of the humerus by maintaining the shoulder in abduction and the elbow in 90°. The therapist will raise his own body by slightly pulling on the anterior capsule and this pull will be maintained for 10-15 seconds and then relax for five seconds and will be performed for about two to three minutes. At this moment the subject will be asked to perform shoulder abduction with no external rotation, while elbow flexion will be maintained throughout.
Study NCT05937776 — intervention group
Intervention type: PROCEDURE
Intervention: Contrast-enhanced Magnetic Resonance Imaging
Description: Undergo PET/contrast-enhanced MRI
Study NCT06544239 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional basketball asymmetric training
Description: This study established two experimental groups, namely the experimental group and the control group. The experimental group received virtual reality device assisted training, while the control group received traditional training
Study NCT05937776 — intervention group
Intervention type: PROCEDURE
Intervention: Positron Emission Tomography
Description: Undergo PET/contrast-enhanced MRI
Study NCT04109599 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PlaySmart
Description: Participants played the developed PlaySmart game over the course of a week.
Study NCT04109599 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PlaySmart Storyline
Description: Participants played through one PlaySmart Storyline during one 1-1.5 hour session.
Study NCT04109599 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Play Smart Mini-Game
Description: Participants played through all levels of the PlaySmart Risk Sense mini-game during one 1-1.5 hour session.
Study NCT05059288 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Non Invasive Ventilation Mask
Description: Oronasal non invasive ventilation mask
Study NCT06372743 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: INTEGREAT-CKD Intervention
Description: The participant is reviewed once in 12 weeks by a CKD-trained APN, during a 30-minute timeslot, an extended duration compared to the timeslot of 10 to 15 minutes that routinely is designated for a recurrent review of a CKD patient in any restructured hospital in Singapore. The review consists of a 15-minute medical review centred on a discussion of the biochemical reports and clinical data relevant to CKD management, and educating on CKD knowledge and lifestyle modification.~Patients self-report the monitored parameters to a community-based nurse through a telehealth AI-based platform. The APN oversees monitoring the community-based parameters and titration of appropriate medications. The APNs have received a Master's in Nursing, with training that is primarily centred on generalist-led care, with additional clinical training in CKD management. They are supported with protocols to detect anomalies in blood pressure trends, glycemia ranges, and abnormalities in fluid status.
Study NCT05676710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linperlisib
Description: Elevated PI3K activity in T-LGL likely plays an important role in the ability of the pathologic cells to avoid homeostatic apoptosis, since inhibition of this pathway leads to apoptosis in the population of cells harboring the pathologic clone. More importantly, the activity of this pathway may represent a kind of Achilles heel for T-LGL in that PI3K inhibitors alone are quite effective at inducing spontaneous apoptosis in the clonal CTLs after a short incubation.
Study NCT05240261 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Quetiapine
Description: Quetiapine 25 mg / day
Study NCT04941443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone Pill
Description: All participants will be given a 5mg methadone tablet to be taken immediately following the misoprostol dose.
Study NCT04941443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: All participants will be provided additional analgesics (ibuprofen 800mg x4 tabs) available for use as needed every eight hours.
Study NCT04934631 — intervention group
Intervention type: OTHER
Intervention: Recording of CBT-ED session.
Description: Therapists will deliver treatment as usual (CBT-ED) to eating disorder patients. Therapy session will be audio recorded.
Study NCT04934631 — intervention group
Intervention type: OTHER
Intervention: Assessment of CBT-ED clinician competence.
Description: Independent raters will assess CBT-ED competence using the Cognitive-Behavioural Therapy Scale for Eating Disorders (CBTS-ED).
Study NCT06131762 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active release technique
Description: This include active release technique for 4 weeks
Study NCT06131762 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positional release technique
Description: This include positional release technique for 4 weeks
Study NCT05260541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60 mg PRAX-114 or 40 mg PRAX-114
Description: Once daily oral treatment for 4 weeks
Study NCT05260541 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily oral treatment for 4 weeks
Study NCT05260541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 mg PRAX-114
Description: Once daily oral treatment for 8 weeks
Study NCT05411575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor 20 MG/ML [Mozobil]
Description: Plerixafor (Mozobil®) continuous intravenous infusion for 7 days
Study NCT05411575 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo continuous intravenous infusion for 7 days
Study NCT05195606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auditory stimulus
Description: Auditory stimulus will be applied to the patients in intervention group A. For the auditory stimulus, the sound recording of the relatives of the patients will be taken and the patients will be listened to with headphones.
Study NCT05195606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tactile stimulus
Description: Tactile stimulus will be applied to the patients in the intervention group B. The tactile stimulus will be performed by the researcher with a foot massage to be applied to the patient.
Study NCT05308212 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu-M Tetra [Inactivated split influenza vaccine] w/p
Description: solution for intramuscular injection, 0.5 ml
Study NCT05308212 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu-M Tetra [Inactivated split influenza vaccine] w/o/p
Description: solution for intramuscular injection, 0.5 ml
Study NCT05308212 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ultrix [Inactivated split influenza vaccine]
Description: solution for intramuscular injection, 0.5 ml